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The identification of broadly reactive and cross-clade 
neutralizing antibodies will facilitate the development 
of a more universally effective vaccine for human im-
munodeficiency virus (HIV). Antibodies in sera from 
individuals infected with Clade B HIV bind native pri-
mary viral isolates, and virus binding correlates with 
neutralization and stable clinical disease. In this study, 
we quantified cross-clade antibody reactivity and neu-
tralization by Clades B and C sera. Primary viral isolates 
were captured by serum IgG bound to anti-human IgG 
and quantitated as p24 released by lysis of captured vi-
rus. Neutralization was determined using PHA-stimu-
lated PBMC. Clade B antibodies reacted more frequently 
with Clade B R5 virus, but positive sera captured quan-
titatively more X4 virus than R5 and R5X4 virus. Clade 
B sera reacted less frequently and captured less Clade 
C virus than Clade B virus. Antibodies in Clade C sera 
captured Clades B and C isolates with equal frequency 
and quantity. There was no difference in neutralization 
of Clade B virus by either group of sera; however, Clade 
C sera neutralized Clade C virus, whereas Clade B sera 
were ineffective against Clade C virus. Thus, there are 
distinct differences in cross-clade reactivity of and neu-
tralization by antibodies induced in response to Clade 
C infection compared to Clade B infection. Understand-
ing antibody responses to native virions after Clade C 
infection and cross clade antibody behavior has impli-
cations for understanding pathogenesis and vaccine de-
velopment.
KEY WORDS: human immunodeficiency virus; neutral-
ization; serum antibody; cross-clade
INTRODUCTION
A major goal of human immunodeficiency virus (HIV) 
vaccine research is to develop an effective vaccine that is 
protective against all clades of HIV-1. Clade B virus pre-
dominates in North America and parts of Europe. Other 
clades are prevalent elsewhere in the world. Clade C vi-
rus constitutes a major fraction of infections in Southern 
and Eastern Africa, India, Nepal, and China. Clade C is 
endemic in parts of Africa where infection and transmis-
sion rates are very high [Essex, 1993; Oelrichs et al., 2000; 
Spira et al., 2003]. India and China have the potential to 
become a major factor in the epidemic in the future, and 
there are already more than 5 million Clade C infections 
in India alone [Arora et al., 2004]. While there is minimal 
interclade diversity within the pol and gag region of HIV-
1, there is considerable inter-and intra-clade variation in 
the env region. To date, a majority of the vaccines being 
tested are based on, or at least have as one component, 
the env region of HIV, based on Clade B isolates. A spe-
cific understanding of limitations of cross-reactive and 
subtype specific Env responses is required to maximize 
the development of a broadly effective HIV-1 vaccine.
While both cross-reactive and subtype-specific CTL re-
sponses, predominantly to gag and pol sequences, have 
been reported [Betts et al., 1997; Cao et al., 1997; Ferrari et 
al., 1997], the humoral response to vaccines and infections 
is directed towards Env, where more diversity is seen. 
Early reports suggested that there is no strict clade de-
pendence of neutralization [Kostrikis et al., 1996; Moore 
et al., 1996; Nyambi et al., 1996; Weber et al., 1996]. It was 
shown that while sera from Clades B and E patients pref-
Published in the Journal of Medical Virology 76: 146–152 (2005).
Accepted February 23, 2005. DOI: 10.1002/jmv.20339. Used by permission.
Copyright 2005, Wiley-Liss. Published online, Wiley InterScience (www.interscience.wiley.com). 
Work was performed at Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Grant sponsor: NIH; Grant numbers: AI26926, P01AI48240. 
Dichotomy in Cross-Clade Reactivity and Neutralization by 
HIV-1 Sera: Implications for Active and Passive Immunotherapy
Lisa A. Cavacini1,2*, Mark Duval1, Ajay Patil1, Charles Wood3,
Kenneth H. Mayer4,5, Ruth M. Ruprecht2,6, and Marshall R. Posner1,2
1Beth Israel Deaconess Medical Center, Boston, Massachusetts,
2Harvard Medical School, Boston, Massachusetts,
3University of Nebraska at Lincoln, Lincoln, Nebraska,
4Fenway Community Health, Boston, Massachusetts,
5Miriam Hospital/Brown University, Providence, Rhode Island,
6Dana-Farber Cancer Institute, Boston, Massachusetts
* Correspondence to L. A. Cavacini: lcavacin@bidmc.harvard.edu 
146
Dichotomy in cross-claDe reactivity anD neutralization by hiv-1 sera: implications for active anD passive immunotherapy 147
erentially reacted with monomeric gp120 from Clades B 
and E isolates, respectively, this preference was not par-
ticularly observed for other clades [Moore et al., 1996]. 
Also, neutralization of primary isolates in these studies 
was sporadic, making interpretation difficult. Further-
more, few sera or isolates were derived from Clade C-
infected individuals. Recently [Bures et al., 2002], it was 
shown that Clade C sera neutralized autologous and het-
erologous Clade C isolates, including geographically di-
verse isolates. Selected sera displayed cross-clade neu-
tralization activity against Clade B T-cell line adapted 
isolates (TCLA) and primary isolates. This suggests that 
antibody responses to Clade C infection may be capable 
of broad efficacy.
Taken together, these results suggest that there may be 
important differences in the presentation of HIV-1 an-
tigens and epitopes to the immune system resulting in 
a different outcome in the immune response to Clade 
C infections. We have also shown that, in addition to 
clade-specific effects, there is heterogeneity of specific 
antibody responses to native primary viral isolates as a 
function of co-receptor usage [Cavacini et al., 2002]. An-
tibodies reactive with intact primary isolates have not 
been studied across clades. Therefore, we have analyzed 
antibody reactivity with and neutralization of primary 
isolate Clades B and C viruses using sera from individ-
uals infected with Clade B virus and Clade C virus. As 
described below, more robust antibody responses are 
observed among Clade C-infected patients; the antibod-
ies were readily cross-reactive with Clades B and C. The 
reciprocal cross-clade binding of Clade B antibodies to 
Clade C viruses is less broad and less robust among the 
Clade B sera tested. These data suggest that studying 
the humoral immune responses of Clade C patients may 
lead to more broadly reactive and effective antibodies for 
therapy and/or vaccine development.
MATERIALS AND METHODS
Clinical Samples and Virus
Subtype B primary isolates, 92HT593, 92US660 from N. 
Halsey, MACS, HIV-189.6 (89.6) from R. Collman, HIV-
1BAL (BAL) from S. Gartner, M. Popovic and R. Gallo, 
and subtype C primary isolate 93MW960 from Dr. Paolo 
Miotti and the UNAIDS Network for HIV Isolation and 
Characterization, and the DAIDS, NIAID were obtained 
through the AIDS Research and Reference Reagent Pro-
gram, Division of AIDS, NIAID, NIH. Clade B X4 isolate 
67970 was obtained from D. Montefiori, Duke University 
Medical School and Clade C R5 isolate 1157 was from the 
laboratory of Dr. Wood.
Informed consent was obtained from all participants in 
this study, and the study was approved by the institu-
tional review boards of the Beth Israel Deaconess Medi-
cal Center and Fenway Community Health Center. Sera 
from Clade B-infected individuals were obtained from 
individuals seen either at the New England Deaconess 
Hospital, Boston MA (now Beth Israel Deaconess Med-
ical Center) or the Fenway Community Health Center, 
Boston, MA for routine care. Sera were obtained from 
Clade C-infected individuals attending an HIV clinic at 
the University Teaching Hospital, in Lusaka, Zambia. 
While CD4 counts, anti-retroviral history, and probable 
seroconversion data were available for some of the Clade 
B-infected individuals, the ability to collect this informa-
tion for the Clade C-infected individuals was not avail-
able at the time of this study. However, all individuals 
in this study were asymptomatic, without AIDS defin-
ing criteria, for a period of time prior to collection of the 
sera or plasma used in this study. While clade specificity 
for each individual in this study was not confirmed by 
sequencing viral isolates for each individual, the clade 
specificity for these cohorts has been established through 
other studies. For example, of the hundreds of isolates 
sequenced from the study site in Zambia, only two were 
not Clade C with one isolate being Clade A and another a 
Clade A/C recombinant. Similarly, with the rare excep-
tion of an individual being infected outside the United 
States (and who was not included in this study), se-
quence analysis of isolates from individuals seen at the 
study sites in Boston, especially in the time period that 
the samples were collected, has exclusively been Clade B.
Reactivity With HIV-1 Infected Cells and Virions
Serum IgG binding to primary HIV isolates was mea-
sured by ELISA as previously described [Cavacini et al., 
1999]. Virus stocks were prepared in PHA-stimulated 
donor PBMC [Cavacini et al., 1998, 1999]. IgG in serum 
was captured onto ELISA plates coated with goat anti-
human IgG (Fc specific) prior to the addition of virus 
stock diluted to 100 ng/ml. The concentration of p24 re-
leased from bound virus by 1% triton was determined by 
ELISA. A cut-off value of 200 pg/ml is considered signif-
icant and serum from HIV seronegative donors captured 
less than 100 pg/ml. Low levels of antibody are defined 
as 200–300 pg/ml, moderate as 300–500 pg/ml, and high 
titers as >500 pg/ml of p24.
Primary Isolate Neutralization Assays
Primary isolate neutralization was measured using an 
assay that quantitates the amount of p24 produced by a 
constant inoculum of virus in PHA stimulated PBMC. In 
this assay, serum was diluted in growth media (RPMI 
1640 with 20%FBS and 5% IL-2), and 50 ml were added 
to 50 ml of viral stock (200TCID50/ml) and incubated for 
1 hr at 378C. After 1 hr, donor PHA-stimulated PBMC (2 
. 105 cells) were added and the plates incubated for 2 hr 
at 378C, 5% CO2. The plates were washed twice, and the 
medium was replaced with fresh growth medium. Seven 
days after the infection was initiated, supernatant was 
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removed and tested for p24 by ELISA. Serum from an 
HIV. seronegative person was included in each experi-
ment, and the p24 values obtained with those samples 
were used to determine percent neutralization.
RESULTS
Prevalence of Virion Specific Antibodies
We have previously reported that the majority of indi-
viduals infected with Clade B HIV had either low or no 
serum IgG antibody reactive with native primary viral 
isolates [Cavacini et al., 1999]; furthermore, virion-spe-
cific antibody in Clade B sera correlated with CD4 counts 
and with neutralizing antibody activity. To further char-
acterize the virion-specific and neutralizing antibody re-
sponse, including the antibody response of individuals 
infected with Clade C HIV, we have analyzed sera from 
asymptomatic individuals infected with Clades B and C 
HIV without opportunistic infections, regardless of anti-
retroviral therapy. Since differential binding of human 
monoclonal antibodies had a virion dependency upon co-
receptor usage [Cavacini et al., 2002], a total of seven iso-
lates, including five Clade B and representing R5, R5X4, 
and X4 isolates and two Clade C isolates (both R5), were 
included in the analysis. Of the 32 asymptomatic Clade 
B-infected individuals, sera from all but one individual 
had specific antibody (>200 pg/ml) against at least one 
Clade B isolate of HIV (data not shown). Similarly, sera 
from all but 2 of the 32 individuals infected with Clade 
C HIV had specific antibody reactive with at least one 
Clade C isolate of HIV (data not shown). Thus, consistent 
with our previous findings [Cavacini et al., 1999], asymp-
tomatic HIV infection correlates with the presence of vi-
rion-specific antibody.
When tested for reactivity with R5X4 primary isolates 
92HT593 and 89.6, a large number of sera from both 
Clade B (Fig. 1A) and Clade C (Fig. 1B) infected individ-
uals were positive for virion-specific antibody. As sum-
marized in Table I, 59% and 41% of sera from Clade B-
infected individuals reacted with 92HT593 and 89.6, 
respectively, while 81% and 59% of Clade C sera were 
reactive with 92HT593 and 89.6, respectively. These dif-
ferences did not achieve statistical significance. Simi-
larly, 59% of sera from Clade B and 84% of sera from 
Clade C-infected individuals reacted with the X4 isolate, 
67970 (Fig. 1C,D). Although there were differences in the 
amount of p24 captured by individual sera, there was no 
statistically significant difference in the incidence of re-
activity. The overwhelming majority of sera from both 
Clades B and C-infected individuals reacted with Clade 
B R5 isolates 92US660 and BaL (Fig. 2A,B). In sharp con-
trast, less than half of the Clade B sera (Fig. 2C) reacted 
with Clade C R5 isolate (1157 or 93MW960), while more 
than 80% of the Clade C reacted with Clade C virus (Fig. 
2D). This was a statistically significant difference in reac-
tivity against Clade C virus (Table I). It should be noted 
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that fewer sera were analyzed for reactivity with Clade 
C isolate 1157 due to limited high-titered stocks of this 
isolate. However, the results obtained with 1157 were 
similar to that reported for 93MW960. Thus, the HIV an-
tibody response of those infected with Clade C HIV dis-
plays broader cross-clade reactivity than the HIV anti-
body response of those infected with Clade B HIV. This 
is not a function of co-receptor usage as Clade B sera re-
acted equally well with R5 Clade B isolates as Clade C 
sera, yet had lower reactivity with R5 Clade C isolates. 
Another indication of the difference in the breadth of re-
activity is the observation that 34% (11 of 32) of Clade 
B infected sera reacted with all isolates tested, whereas 
56% (18 of 32) of Clade C-infected sera reacted with all 
isolates (data not shown).
Despite a difference in the incidence of reactivity be-
tween Clades B and C sera, analysis of the raw individual 
data (not shown) indicated that there is little difference 
in the amount of virus captured by sera for most isolates. 
Using the criteria of capture of more than 500 pg/ml as 
indication of high titer virion specific antibody, similar 
results were obtained with sera from both Clades B and 
C for isolates 92US660 (13% for Clade B, 9% for Clade 
C), 89.6 (22% for Clade B, 19% for Clade C), BaL (22% 
for Clade B, 31% for Clade C), and 93MW960 (19% for 
Clade B, 16% for Clade C). For the R5X4 isolate 92HT593, 
more individuals infected with Clade C HIV (47%) had 
high primary isolate-specific antibody than individuals 
infected with Clade B HIV (25%). Similarly, 59% of in-
dividuals infected with Clade C had high primary iso-
late-specific antibody reactive with the X4 isolate 67970, 
whereas fewer Clade B sera (38%) had high specific an-
tibody reactive with this isolate. Ten and 13 of the 32 in-
dividuals infected with Clade C or Clade B HIV, respec-
tively, did not mount a high titer virion specific antibody 
response against any isolate.
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Neutralization of Primary Isolates by Sera
Sera from HIV Clades B and C-infected individuals 
were tested for the ability to neutralize three Clade B 
(92HT593 {R5X4}, 92US660 {R5}, and 67970 {X4}) isolates, 
and one Clade C (93MW960 {R5}) isolate. Values are ex-
pressed as the dilution of sera resulting in 90% neutral-
ization (IC90). The higher the IC90 value, the more the 
sera can be diluted indicating more potent neutralizing 
activity. As shown in Table II, regardless of co-receptor 
use, there were no significant differences in neutraliza-
tion between Clades B and C sera for the Clade B isolates. 
In contrast, there was a significant difference in the neu-
tralization of Clade C. Sera from Clade B infected indi-
viduals did not neutralize Clade C virus. In contrast, 40% 
of Clade C sera neutralized Clade C virus with a range of 
IC90 titers of 0–117 (P < 0.04).
When neutralization titers and virion specific anti-
body are correlated, additional cross-clade differences 
are apparent. For the Clade B R5X4 isolate 92HT593, sera 
with virion-specific antibody had neutralization activity 
(IC90 > 10) as shown in Figure 3A. However for Clade B 
sera, the correlation was not tight. While neutralizing, a 
higher virion-specific antibody level did not necessarily 
indicate a greater neutralization activity. Similar results 
were obtained for Clade B sera and the Clade B R5 iso-
late 92US660 (Fig. 3B). Moreover, despite high HIV spe-
cific antibody, only a quarter of the Clade C sera with 
virion-specific antibody neutralized 92US660 (Fig. 3B). 
Also, only half of Clade B or C sera with virion-specific 
antibody neutralized the X4 isolate 67970 (Fig. 3C) and 
none of the Clade B sera neutralized Clade C R5 virus 
93MW960 (Fig. 3D), despite more than 40% of the sera 
having virion specific antibody. In addition, only half of 
the virion specific antibody positive Clade C sera neu-
tralized Clade C virus. Despite a lack of direct correla-
tion between the concentration of virion specific antibod-
ies and neutralization titers, with the exception of two 
sera with the Clade B R5 isolate, 92US660, all neutraliz-
ing sera had virion-specific antibodies. Thus, while the 
presence of virus-specific antibody did not predict neu-
tralization activity, specific antibody was essential for 
neutralization activity to be present in the sera. This im-
plies that some virus-specific antibody is not directed at 
neutralizing epitopes.
DISCUSSION
We have shown previously that the majority of indi-
viduals infected with Clade B HIV had either low or no 
serum IgG antibody reactive with native primary isolate 
virions [Cavacini et al., 1999]. In this report, we studied 
virus-specific antibodies from asymptomatic individuals 
infected with either Clade B or C HIV, and cross-clade 
virion binding and neutralization by serum antibodies 
from these two populations. Consistent with our previ-
ous report, native virion-specific antibody was necessary 
for viral neutralization, albeit it did not predict neutral-
ization activity. That is, sera with robust neutralization 
activity had viral specific antibody, while only some sera 
with virus-specific antibody had neutralizing antibody. 
It is not surprising that among the multiple assays and 
individuals studied, there are rare individuals with low 
titers of virion specific antibody but with high levels of 
neutralizing antibody to an individual isolate. This can 
be explained by heterogeneity in both the polyclonal an-
tibody response and virus (autologous virus vs. test vi-
rus in assay).
It has been suggested that the failure of most neutral-
izing human monoclonal antibodies to react substan-
tially with native primary viral isolates is the result of 
non-functional spikes on the virons suggesting that the 
viral capture assay is a limited assay for the study of an-
tibody/viral interactions resulting in viral neutralization 
[Poignard et al., 2003]. However, it can be argued that the 
utility of the viral capture assay is a function of the pa-
rameters of the assay [Cavacini and Posner, 2004]. For 
example, differences in the incorporation of specific cel-
lular host components in the viral membrane as a func-
tion of the cell type used to produce progeny virus has 
major implications for infectivity, gp120/41 structure, 
and viral neutralization. More importantly, the use of a 
neutralizing antibody to capture virus has been shown 
to result in reduced viral output, which is to be expected, 
and which may influence interpretation of the results. 
Failure of neutralizing antibodies to bind substantially 
to primary isolate virions may reflect virion camouflage. 
Non-V3 neutralizing epitopes are not exposed on the pri-
mary HIV isolates until the virus is in proximity of a tar-
get cell or in the post-CD4 binding state. Further, the im-
mune system is confounded by the immunogenicity of 
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the exposed variable loops while neutralizing epitopes 
are not generally available to immune cells or serum an-
tibody. For those sera with both high virion binding an-
tibody and neutralization, it can be hypothesized that V3 
loop antibody, which readily reacts with virions, is a ma-
jor contributor to virion binding and neutralization for 
these sera. Further analysis of the epitopes recognized by 
the antibodies that capture virus, and the contribution of 
those antibodies to in vivo viral inactivation or neutral-
ization are underway. Finally, the contribution of syn-
ergy between non-neutralizing serum antibodies, which 
bind primary HIV isolates and neutralizing antibodies in 
in vitro viral neutralization remains to be determined, al-
though synergy in this setting has been demonstrated for 
human monoclonal antibodies [Cavacini et al., 2002].
Antibodies raised in response to HIV-1 vaccines in hu-
mans and animals react with HIV but rarely neutralize 
primary isolates [Mascola et al., 1996; Beddows et al., 1999; 
Bures et al., 2000]. Early reports suggested that there is no 
strict clade dependence of neutralization [Kostrikis et al., 
1996; Moore et al., 1996; Nyambi et al., 1996; Weber et al., 
1996]. In this study, serum antibodies in Clade C-infected 
individuals reacted with Clade C HIV as well as cross-
reacted with Clade B HIV. However, virion-reactive an-
tibodies in individuals infected with Clade B HIV were 
not as robustly cross-reactive with Clade C HIV. Consis-
tent with this result, sera from Clade C-infected individ-
uals have been shown to broadly neutralize autologous 
and heterologous Clade C isolates and Clade B isolates 
[Bures et al., 2002]. Of interest, it has been reported that 
a disproportionate number of African women, as com-
pared to African men and European men and women, 
had high-titer, broadly cross-reactive neutralizing anti-
bodies [Beirnaert et al., 2000; Donners et al., 2002].
In conclusion, there is a significant difference in the 
quality of the humoral response to Clade C virus com-
pared to Clade B virus. Antibodies from individuals in-
fected with Clade C HIV-1 have broader cross-reactivity 
in both primary virion binding and neutralizing activity 
than antibodies from individuals infected with Clade B 
HIV. Further study of the humoral response of Clade C 
infected individuals, in terms of antibody reactivity and 
presentation of viral epitopes to the immune system, 
may lead to more broadly reactive and effective antibod-
ies for therapy and/or vaccine development.
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